(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
The beauty advent calendar boom is here. Sephora kids are all in. - 24 Excellent Remote Headphones of 2024
- 3Partake in the Outside: Senior-Accommodating Exercises for 2024
- 4NASA Artemis 2 astronauts to make historic moon flyby today. Here's what to expect hour by hour (timeline)
- 5Banks for High Fixed Store Rates: Augment Your Investment funds
- Doctor's orders? ‘Belly laugh at least two to five days a week'
- Kidneys from Black donors are more likely to be thrown away − a bioethicist explains why
- NASA set for first crewed moon return in over half a century
- I asked ChatGPT who would win a Golden Globes. Here's what it got right — and totally wrong.
- Oldest sequenced RNA reveals details about a mammoth’s final moments 40,000 years
- Full Supreme Court to hear challenge to Judicial Selection Committee law
- Sports Shoes of 2024: Upgrade Execution and Solace
- James Webb Space Telescope's mysterious 'little red dots' may be black holes in disguise
- Hundreds of kilos of protected plant seized by Israel Nature and Parks Authority in Golan
